Curi Bio has raised $16.0M in total across 2 funding rounds.
Curi Bio's investors include Dynamk Capital.
Curi Bio is a Seattle-based biotechnology company that develops human-relevant platforms integrating induced pluripotent stem cell (iPSC)-derived cells, 3D engineered tissue models, biosystems for functional analysis, and AI/ML-enabled data analytics to accelerate drug discovery and preclinical testing.[1][2][4] It serves pharmaceutical and biotech researchers by providing predictive models for cardiac, skeletal muscle, neuromuscular, and metabolic diseases, solving the problem of inaccurate animal models and early-stage preclinical data through structurally mature, human-specific tissues that deliver clinically relevant functional readouts like contractility, electrophysiology, and calcium transients.[1][2][3] Recent growth includes a $10 million Series B funding round closed in December 2025 to scale tissue production, expand lab capabilities, increase assay capacity, and broaden into more tissue types such as ALS modeling.[1][4]
Founded in 2015 as NanoSurface Biomedical, Curi Bio (rebranded from its former name) emerged from University of Washington research, leveraging expertise in cell and tissue engineering.[4][7] Key figures include CEO and management team members like Chief Science Officer Nicholas Geisse, with a Scientific Advisory Board featuring experts from Johns Hopkins, University of Washington, and industry leaders such as the former CMO of AskBio (Bayer) and President of ASGCT.[8] The idea stemmed from advancing drug discovery via human iPSCs reprogrammed into disease-relevant cell types like cardiomyocytes and skeletal muscle cells, organized into 3D microphysiological systems for better biological mimicry.[1][2] Early traction built through proprietary platforms like Mantarray for contractility analysis and NanoSurface plates for tissue maturation, evolving into a full workflow spanning preclinical drug development, culminating in the 2025 Series B to fuel expansion.[1][3][4]
Curi Bio stands out in biotech tooling through its integrated, end-to-end platform emphasizing human iPSC-derived models over animal testing:
Curi Bio rides the wave of human-on-a-chip and organoid technologies, addressing the 90%+ preclinical failure rate in drug development by replacing animal models with iPSC-based systems that capture human genetic diversity and organ-level interactions.[1][2] Timing aligns with surging demand for human-relevant data amid regulatory pushes (e.g., FDA Modernization Act 2.0 favoring non-animal testing) and AI-driven drug discovery, amplified by post-2020 biotech funding resurgence.[1][4] Market tailwinds include explosive growth in cell therapy, gene editing (e.g., CRISPR for neuromuscular diseases), and precision medicine, where Curi's contractile/excitable tissue focus supports cardio-oncology, rare diseases like ALS/DMD, and metabolic disorders.[1][5] It influences the ecosystem by partnering with pharma for R&D workflows, de-risking pipelines, and enabling scalable assays that feed AI models for better hit-to-lead decisions.[2]
Curi Bio's $10M Series B positions it to dominate human tissue platforms, with near-term priorities on automating production, expanding cardiac/metabolic/neuromuscular models, and boosting partner assay throughput.[1][4] Trends like AI integration for predictive analytics, multi-organ chips, and non-animal regulatory mandates will propel growth, potentially capturing share in the $5B+ preclinical tools market. Its influence may evolve from tooling provider to ecosystem enabler, powering breakthroughs in regenerative medicine and personalized drugs—cementing its role as a cornerstone for human-centric biotech innovation.[1][2]
Curi Bio has raised $16.0M across 2 funding rounds. Most recently, it raised $10.0M Series A in December 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2021 | $10.0M Series A | Dynamk Capital | |
| Mar 1, 2021 | $6.0M Series A | Dynamk Capital |
